{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034565","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.443315+00:00","generated_at":"2026-05-30T01:43:11.769418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zevra Q3 net loss $33.2M; FDA approval of MIPLYFFA for NPC marks key milestone","bullets":["Net loss of $33.2M ($0.69 per share) vs. $10.4M loss in Q3 2023; revenue $3.7M from French EAP and AZSTARYS royalties.","FDA approved MIPLYFFA (arimoclomol) on Sept. 20 for Niemann-Pick type C; first-ever NPC drug approved.","Cash, equivalents, and investments $95.5M as of Sept. 30; cash runway forecast into 2027, excluding PRV sale.","Completed $64.5M public offering of 10.6M shares at $6.50; closed Iowa/Virginia labs, outsources early R&D.","OLPRUVA revenue minimal; 90 prescription enrollment forms for MIPLYFFA received by Oct. 31, 30% approved for reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034565","json":"https://secwatch.observer/filing/0001437749-24-034565.json","markdown":"https://secwatch.observer/filing/0001437749-24-034565.md","text":"https://secwatch.observer/filing/0001437749-24-034565.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924034565/0001437749-24-034565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924034565/zvra20240819_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:43:11.769418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}